Drug-Free Management Tools Provide Alternatives to Opioids in Kidney Cancer

An expert from University Hospitals touches on pain management guidelines that highlight moderate evidence in support of acupuncture, reflexology, and acupressure and massage as tools to manage general pain in patients with cancer.

During Kidney Cancer Awareness Month 2023, Santosh Rao, MD, spoke with CancerNetwork® about evidence from the “Integrative Medicine for Pain Management in Oncology” guidelines from the Society for Integrative Oncology (SIO) and the American Society for Clinical Oncology (ASCO) concerning the efficacy of integrative medicine for patients with solid tumors such as kidney cancer.

Although there was only moderate evidence supporting techniques such as acupuncture and reflexology in the management of general cancer pain and musculoskeletal pain, Rao, medical director of integrative oncology for University Hospitals Connor Whole Health and president-elect for the SIO, stated that these integrative strategies could be a safe alternative for managing pain compared with opioids.

Transcript:

I’ll go over the pain guidelines; it was pretty conservative. Although we may expand these guidelines in the future or the evidence might be more robust, it was really a statement of where we’re at right now. For general cancer pain, there was moderate evidence for the use of acupuncture, reflexology, or acupressure and massage. There was weak evidence for things like yoga and guided imagery.

For neuropathy, there was weak evidence for acupuncture, reflexology, or acupressure. For procedural pain, hypnosis had moderate evidence. For pain during palliative care, massage had moderate evidence. For surgical pain, acupuncture and music therapy had weak evidence.

You contrast [the guidelines] with the fact that these [therapies] are extremely safe. My interest in this kind of approach is that the contrast to using these modalities is to usually use opioids, which have lots of potential [adverse] effects. If you can potentially reduce opioid use with all their [adverse] effects, even if it’s just limiting the amount of opioid use, then that’s a win. You’re not going to get [adverse] effects from music therapy or massage, for example. And we have guidelines around that; it’s important for people to be educated on the safety guidelines when we use these things. That has been really useful.

Reference

Mao JJ, Ismaila N, Bao T, et al. Integrative medicine for pain management in oncology: Society for Integrative Oncology-ASCO guideline. J Clin Oncol. 2022;40(34):3998-4024. doi:10.1200/JCO.22.01357

Related Videos
PRGN-3005 autologous UltraCAR-T cells appear well-tolerated and decreases tumor burden in a population of patients with advanced platinum-resistant ovarian cancer.
Sara M. Tolaney, MD, MPH, discusses how, compared with antibody-drug conjugates, chemotherapy produces low response rates and disease control in the treatment of those with hormone receptor–positive, HER2-negative metastatic breast cancer.
Hope Rugo, MD, speaks to the importance of identifying patients with aromatase inhibitor–resistant, hormone receptor–positive, HER2-negative advanced breast cancer who are undergoing treatment with capivasertib/fulvestrant who may be at a high risk of developing diabetes or hyperglycemia.
Sara M. Tolaney, MD, MPH, describes the benefit of sacituzumab govitecan for patients with HER2-low metastatic breast cancer seen in the final overall survival analysis of the phase 3 TROPiCS-02 study.
An expert from Vanderbilt University Medical Center says that patients with relapsed/refractory multiple myeloma may be able to live a normal life following response to salvage treatment with bispecific monoclonal antibodies.
Andrew J. Armstrong, MD, MSc, spoke about the recent approval of olaparib plus abiraterone acetate and prednisone in patients with BRCA-mutant metastatic castration-resistant prostate cancer.
For clinicians practicing in the community, constant communication and education from those in institutions may help to produce the best quality of care for patients with multiple myeloma.
Ashley E. Rosko, MD, specializes in multidisciplinary care for elderly patients with multiple myeloma, and how to make treatment most accessible to them.
At first relapse, novel therapies are offered to patients with multiple myeloma at The Ohio State University Comprehensive Cancer Center-The James.
Ashley E. Rosko, MD, highlights potential changes on the horizon to the standard of care in multiple myeloma therapy, and discussed the personalization of treatment based on transplant eligibility.
Related Content